The ORANGE II Trial: An International Multicenter Randomised Controlled Trial of Optimised Surgical Recovery After Left Lateral Hepatic Sectionectomy: Open Versus Laparoscopic Surgery Within an Enhanced Recovery Programme
Recent developments in liver surgery include the introduction of laparoscopic surgery and
enhanced recovery programmes. Laparoscopic surgery and enhanced recovery programmes both
focus on faster recovery and consequently shorter hospital length of stay.
The ORANGE-II trial is a prospective randomised controlled parallel group superiority trial
with a double-blinded experimental and a prospective registry design to determine whether
laparoscopic surgery is to be preferred over open surgery in patients undergoing a left
lateral hepatic sectionectomy within an enhanced recovery programme. The experimental
design produces two randomised arms; (a) open LLS and (b) laparoscopic LLS. An additional
registry arm will be based on surgeons/patients that do not want to be randomised because
they have an explicit preference for either the laparoscopic LLS or for the open LLS (c).
The primary endpoint of the ORANGE II trial is time to functional recovery. The functional
recovery criteria consist of adequate pain control with oral analgetics only, mobility
restored to an independent level, absence of intravenous fluid administration, ability to
eat solid foods and finally a normal or decreasing serum bilirubin level. A patient is fully
functionally recovered when all of the five criteria are satisfied.
Secondary endpoints of this trial are postoperative length of hospital stay, readmission
percentage, (liver specific) morbidity, quality of life, body image and cosmetic result,
hospital and societal costs during one year and long-term incidence of incisional hernias.
The ORANGE-II trial is a randomised controlled multicentre trial that will provide evidence
on the merits of laparoscopic surgery in patients undergoing a left lateral hepatic
sectionectomy and participating in an enhanced recovery programme.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment
Time to functional Recovery
The functional recovery criteria consist of adequate pain control with oral analgetics only, mobility restored to an independent level, absence of intravenous fluid administration, ability to eat solid foods and finally a normal or decreasing serum bilirubin level. A patient is fully functionally recovered when all of the five criteria are satisfied. It is medically justified to discharge patients when the criteria for full functional recovery are met and if the patient is willing to go home.
Date the functional recovery criteria are met
No
Ronald M van Dam, MD
Study Director
Maastricht University Medical Centre
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
MEC 08-2-110
NCT00874224
January 2010
July 2014
Name | Location |
---|